FDA Mandates New Warning for GLP-1 Drugs Amid Potential Blindness Risk

The US Food and Drug Administration (FDA) has directed manufacturers of GLP-1 weight loss drugs, including popular medications like Ozempic, Wegovy, and Mounjaro, to include a warning label concerning a potential link to permanent vision loss. This decision stems from research that identified a connection between Glucagon-like peptide-1 (GLP-1) medications, used for obesity and diabetes management, and a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to blindness.

The FDA's bulletin, issued late Monday, cited clinical trial data, observational studies, and a 2024 article that investigated possible associations between GLP-1 drugs and NAION. This article specifically prompted the FDA's further review into the matter.

“The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications,” the FDA stated in its bulletin. The agency further elaborated that NAION is a rare condition that can cause sudden, painless vision decrease in one eye, potentially resulting in permanent vision loss.

According to the FDA, patients with a prior history of NAION face an elevated risk. The health regulator advised healthcare providers to consider informing patients about discontinuing GLP-1 medications if signs of NAION appear, unless the treatment benefits significantly outweigh the risks. Medications such as Zepbound and Soliqua are also subject to this new warning label requirement.

The FDA's analysis of 126 randomized, controlled clinical trials involving various GLP-1 RAs indicated an occurrence rate of 6.4 NAION cases per 100,000 person-years (PY) among patients treated with these drugs, compared to 3.8 NAION cases per 100,000 PY for those on placebo or non-GLP-1 RA glucose-lowering medications. Despite this, Novo Nordisk, the manufacturer of Ozempic and Wegovy, has stated that “available research does not establish that GLP-1 medications cause NAION.” Nevertheless, the FDA is firm in its directive for drug manufacturers to update their labeling in the warnings and precautions section regarding the potential increased risk of NAION associated with these medications.